These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 18567278)

  • 21. Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles.
    Griesinger G; Kolibianakis EM; Papanikolaou EG; Diedrich K; Van Steirteghem A; Devroey P; Ejdrup Bredkjaer H; Humaidan P
    Fertil Steril; 2007 Sep; 88(3):616-21. PubMed ID: 17451691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results with GnRH antagonist protocols are equivalent to GnRH agonist protocols in comparable patient populations.
    Luna M; Vela G; McDonald CA; Copperman AB
    J Reprod Med; 2012; 57(3-4):123-8. PubMed ID: 22523871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gonadotropin-releasing hormone agonist/antagonist conversion with estrogen priming in low responders with prior in vitro fertilization failure.
    Fisch JD; Keskintepe L; Sher G
    Fertil Steril; 2008 Feb; 89(2):342-7. PubMed ID: 17562336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant follicle-stimulating hormone on follicular fluid levels of adhesion molecules during in vitro fertilization.
    Fornaro F; Cobellis L; Mele D; Tassou A; Badolati B; Sorrentino S; De Lucia D; Colacurci N
    Fertil Steril; 2007 Jan; 87(1):39-47. PubMed ID: 17084393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial.
    Galindo A; Bodri D; Guillén JJ; Colodrón M; Vernaeve V; Coll O
    Gynecol Endocrinol; 2009 Jan; 25(1):60-6. PubMed ID: 19165664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting.
    Ho Yuen B; Nguyen TA; Cheung AP; Leung PC
    Fertil Steril; 2009 Aug; 92(2):499-507. PubMed ID: 18706551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gonadotropin-releasing hormone agonist or human chorionic gonadotropin for final oocyte maturation in an oocyte donor program.
    Erb TM; Vitek W; Wakim AN
    Fertil Steril; 2010 Feb; 93(2):374-8. PubMed ID: 19171336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Biological assessment criteria during antagonist protocols].
    Plachot M
    J Gynecol Obstet Biol Reprod (Paris); 2004 Oct; 33(6 Pt 2):3S32-5. PubMed ID: 15643685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing GnRH agonist long protocol and GnRH antagonist protocol in outcome the first cycle of ART.
    Firouzabadi RD; Ahmadi S; Oskouian H; Davar R
    Arch Gynecol Obstet; 2010 Jan; 281(1):81-5. PubMed ID: 19357861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcomes using a flexible regimen of GnRH-antagonists and a 'step-up' of additional gonadotropins in donor oocyte cycles.
    Barker MA; Christianson MS; Schouweiler CM; Lindheim SR
    Curr Med Res Opin; 2007 Sep; 23(9):2297-302. PubMed ID: 17697455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Premature luteinization and in vitro fertilization outcome in gonadotropin/gonadotropin-releasing hormone antagonist cycles in women with polycystic ovary syndrome.
    Segal S; Glatstein I; McShane P; Hotamisligil S; Ezcurra D; Carson R
    Fertil Steril; 2009 May; 91(5):1755-9. PubMed ID: 18394616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The type of GnRH analogue used during controlled ovarian stimulation influences early embryo developmental kinetics: a time-lapse study.
    Muñoz M; Cruz M; Humaidan P; Garrido N; Pérez-Cano I; Meseguer M
    Eur J Obstet Gynecol Reprod Biol; 2013 Jun; 168(2):167-72. PubMed ID: 23351671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GnRH agonist versus GnRH antagonist in ovarian stimulation: the influence of body mass index on in vitro fertilization outcome.
    Rabinson J; Meltcer S; Zohav E; Gemer O; Anteby EY; Orvieto R
    Fertil Steril; 2008 Feb; 89(2):472-4. PubMed ID: 17582402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early ovarian hyperstimulation syndrome is completely prevented by gonadotropin releasing-hormone agonist triggering in high-risk oocyte donor cycles: a prospective, luteal-phase follow-up study.
    Bodri D; Guillén JJ; Trullenque M; Schwenn K; Esteve C; Coll O
    Fertil Steril; 2010 May; 93(7):2418-20. PubMed ID: 19800620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Follicular fluid concentrations of IGF-I, IGF-II, IGFBP-3, VEGF, AMH, and inhibin-B in women undergoing controlled ovarian hyperstimulation using GnRH agonist or GnRH antagonist.
    Kaya A; Atabekoglu CS; Kahraman K; Taskin S; Ozmen B; Berker B; Sonmezer M
    Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):167-71. PubMed ID: 22776750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GnRH antagonists.
    Coccia ME; Comparetto C; Bracco GL; Scarselli G
    Eur J Obstet Gynecol Reprod Biol; 2004 Jul; 115 Suppl 1():S44-56. PubMed ID: 15196716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Oocyte and embryo quality and outcome of ICSI cycles in patients with polycystic ovary syndrome (PCOS) versus normo-ovulatory].
    Kdous M; Chaker A; Zhioua A; Zhioua F
    J Gynecol Obstet Biol Reprod (Paris); 2009 Apr; 38(2):133-43. PubMed ID: 19179017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of endometrial receptivity.
    Orvieto R; Meltzer S; Rabinson J; Zohav E; Anteby EY; Nahum R
    Fertil Steril; 2008 Oct; 90(4):1294-6. PubMed ID: 18178197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective trial comparing oocyte donor ovarian response and recipient pregnancy rates between suppression with gonadotrophin-releasing hormone agonist (GnRHa) alone and dual suppression with a contraceptive vaginal ring and GnRH.
    Martínez F; Boada M; Coroleu B; Clua E; Parera N; Rodríguez I; Barri PN
    Hum Reprod; 2006 Aug; 21(8):2121-5. PubMed ID: 16632462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.